Established in 1977, EIKO LifeSciences Limited is actively involved in the manufacturing, supply, and global export of Speciality Chemicals and Pharma Intermediates. The company caters to both domestic and international markets, distributing its products across the globe.
The diverse product portfolio finds applications across several sectors, including Pharmaceuticals, Agrochemicals, Aroma Chemicals, Electronic Chemicals, and various others.
Eiko LifeSciences has set up a dedicated manufacturing facility at MIDC, Badlapur, and has strategically collaborated with numerous job-workers for streamlined manufacturing processes.
Narendra Investments (delhi) Ltd Stock Quote #
- Open: ₹57.97
- High – Low: ₹57.97 – ₹51.01
- Previous Close: ₹56.55
- Total Traded Value: 35,846
- Updated On: Aug 11, 2023 4:00 PM
Eiko Lifesciences Rights Issue 2023 Detail #
| Issue Open | Jul 17, 2023 – Jul 26, 2023 |
| Security Name | Eiko Lifesciences Limited |
| Issue Size (Shares) | 5,544,178 |
| Issue Size (Amount) | ₹24.95 Crores |
| Issue Price | ₹45 per share |
| Face Value | ₹10 per share |
| Listing At | BSE |
| Terms of Payment | The amount of Rs. 13.50 per Rights Equity Share (including premium of Rs. 10.50) is to be paid on the Application. Balance to be paid in not more than two calls as determined by the Board. |
| Entitlement | 2 Rights Equity Share(s) for every 3 fully paid-up Equity Shares held on Record Date |
Eiko Lifesciences Rights Issue 2023 Issue Timetable #
| Last Date to buy shares | Jul 6, 2023 |
| Record Date | Jul 7, 2023 |
| Credit of Rights Entitlements | Jul 12, 2023 |
| Bid/Offer Opens On | Jul 17, 2023 |
| Renunciation of Rights Entitlements | Jul 20, 2023 |
| Bid/Offer Closes On | Jul 26, 2023 |
| Deemed Date of Allotment | Aug 3, 2023 |
| Credit Date | Aug 4, 2023 |
| Listing Date | Aug 10, 2023 |
Company Financials #
| Period Ended | Total Assets | Total Revenue | Profit After Tax |
|---|---|---|---|
| 31-Mar-21 | 16.61 | 12.45 | 0.61 |
| 31-Mar-22 | 34.89 | 26.09 | 0.71 |
| Amount in ₹ Crore | |||
Objects of the Issue: #
The Company proposes to utilize the net proceeds from the Issue towards funding the following objects:
- Funding incremental working capital requirements of our Company.
- To meet General corporate purposes.
- To meet the expenses of the Issue.
Eiko Lifesciences Rights Issue 2023 Documents #
Company Contact Information #
Eiko Lifesciences Limited
604, Centrum, Opp. TMC Office,
Near Satkar Grande Hotel, Wagle Estate,
Thane – 400604Phone: 022-2539 0009
Email: investor.relations@eikolifesciences.com
Website: https://www.eikolifesciences.com/
604, Centrum, Opp. TMC Office,
Near Satkar Grande Hotel, Wagle Estate,
Thane – 400604Phone: 022-2539 0009
Email: investor.relations@eikolifesciences.com
Website: https://www.eikolifesciences.com/
Eiko Lifesciences Rights Issue 2023 Registrar #
- Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: rightsissue@bigshareonline.com
Website: https://ipo.bigshareonline.com/ipo_status.html
